07.28.26 -- FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy

Review of ACMG 2026 Genetic Therapies Bootcamp, including gene therapy, gene editing, ASOs, rare disease trial design, and the evolving role of genetics professionals.

Explore how different filter paper grades deliver reliable performance for precision analyses, as well as how ash levels, retention, and strength vary across ashless and hardened options.

In cell processing, rigid, single-function equipment can lead to inefficiencies, wasted space, and scheduling conflicts. A versatile approach can help teams do more with less.

There is no one-size-fits-all model for AAV gene therapy products when it comes to viral clearance studies. Here, we address some of the questions concerning viral clearance studies for AAV vectors.

Scalable rAAV production is achievable with a transient cell line and optimized bioreactor setup, delivering high titers and reduced impurities, now validated at 200 L scale for commercial readiness.

Understanding how upstream control, downstream efficiency, and process robustness scale together is essential for protecting supply and expanding patient access.

See how a multiplex digital PCR approach enables accurate, reproducible VCN determination in gamma‑retrovirus–transduced CAR‑T cells, supporting streamlined workflows and confident decision‑making.

Learn how early stable CHO expression data reveals manufacturability issues in complex antibodies that transient screening misses, with case studies showing how this changes lead selection.

Industry collaboration and data transparency help quantify single-use plastic waste from antibody production, driving sustainable processing solutions.

Optimizing TFF in viral vector workflows can reduce processing time while improving yield. Comparing TMP and permeate control strategies highlights key trade-offs to guide your purification decisions.